Cargando…

Molecular pathology and clinical implications of diffuse glioma

The prognosis for diffusely infiltrating gliomas at World Health Organization (WHO) grade 2–4 remains dismal due to their heterogeneity. The rapid development of genome-wide molecular-profiling-associated studies has greatly promoted the accuracy of glioma classification. Thus, the latest version of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chai, Ruichao, Fang, Shengyu, Pang, Bo, Liu, Yuqing, Wang, Yongzhi, Zhang, Wei, Jiang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106158/
https://www.ncbi.nlm.nih.gov/pubmed/36728558
http://dx.doi.org/10.1097/CM9.0000000000002446
_version_ 1785026366639439872
author Chai, Ruichao
Fang, Shengyu
Pang, Bo
Liu, Yuqing
Wang, Yongzhi
Zhang, Wei
Jiang, Tao
author_facet Chai, Ruichao
Fang, Shengyu
Pang, Bo
Liu, Yuqing
Wang, Yongzhi
Zhang, Wei
Jiang, Tao
author_sort Chai, Ruichao
collection PubMed
description The prognosis for diffusely infiltrating gliomas at World Health Organization (WHO) grade 2–4 remains dismal due to their heterogeneity. The rapid development of genome-wide molecular-profiling-associated studies has greatly promoted the accuracy of glioma classification. Thus, the latest version of the WHO classification of the central nervous system tumors published in 2021 has incorporated more molecular biomarkers together with histological features for the diagnosis of gliomas. Advanced usage of molecular pathology in clinical diagnostic practice provides also new opportunities for the therapy of patients with glioma, including surgery, radiotherapy and chemotherapy, targeted therapy, immunotherapy, and more precision clinical trials. Herein, we highlight the updates in the classification of gliomas according to the latest WHO guidelines and summarize the clinically relevant molecular markers by focusing on their applications in clinical practice. We also review the advances in molecular features of gliomas, which can facilitate the development of glioma therapies, thereby discussing the challenges and future directions of molecular pathology toward precision medicine for patients with glioma.
format Online
Article
Text
id pubmed-10106158
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-101061582023-04-17 Molecular pathology and clinical implications of diffuse glioma Chai, Ruichao Fang, Shengyu Pang, Bo Liu, Yuqing Wang, Yongzhi Zhang, Wei Jiang, Tao Chin Med J (Engl) Review Articles The prognosis for diffusely infiltrating gliomas at World Health Organization (WHO) grade 2–4 remains dismal due to their heterogeneity. The rapid development of genome-wide molecular-profiling-associated studies has greatly promoted the accuracy of glioma classification. Thus, the latest version of the WHO classification of the central nervous system tumors published in 2021 has incorporated more molecular biomarkers together with histological features for the diagnosis of gliomas. Advanced usage of molecular pathology in clinical diagnostic practice provides also new opportunities for the therapy of patients with glioma, including surgery, radiotherapy and chemotherapy, targeted therapy, immunotherapy, and more precision clinical trials. Herein, we highlight the updates in the classification of gliomas according to the latest WHO guidelines and summarize the clinically relevant molecular markers by focusing on their applications in clinical practice. We also review the advances in molecular features of gliomas, which can facilitate the development of glioma therapies, thereby discussing the challenges and future directions of molecular pathology toward precision medicine for patients with glioma. Lippincott Williams & Wilkins 2022-12-20 2023-01-02 /pmc/articles/PMC10106158/ /pubmed/36728558 http://dx.doi.org/10.1097/CM9.0000000000002446 Text en Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Review Articles
Chai, Ruichao
Fang, Shengyu
Pang, Bo
Liu, Yuqing
Wang, Yongzhi
Zhang, Wei
Jiang, Tao
Molecular pathology and clinical implications of diffuse glioma
title Molecular pathology and clinical implications of diffuse glioma
title_full Molecular pathology and clinical implications of diffuse glioma
title_fullStr Molecular pathology and clinical implications of diffuse glioma
title_full_unstemmed Molecular pathology and clinical implications of diffuse glioma
title_short Molecular pathology and clinical implications of diffuse glioma
title_sort molecular pathology and clinical implications of diffuse glioma
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106158/
https://www.ncbi.nlm.nih.gov/pubmed/36728558
http://dx.doi.org/10.1097/CM9.0000000000002446
work_keys_str_mv AT chairuichao molecularpathologyandclinicalimplicationsofdiffuseglioma
AT fangshengyu molecularpathologyandclinicalimplicationsofdiffuseglioma
AT pangbo molecularpathologyandclinicalimplicationsofdiffuseglioma
AT liuyuqing molecularpathologyandclinicalimplicationsofdiffuseglioma
AT wangyongzhi molecularpathologyandclinicalimplicationsofdiffuseglioma
AT zhangwei molecularpathologyandclinicalimplicationsofdiffuseglioma
AT jiangtao molecularpathologyandclinicalimplicationsofdiffuseglioma